Jiangsu Province’s 11 enterprises have made it to the list of China’s top 100 pharmaceutical companies, according to the latest ranking released at the 38th China Pharmaceutical Industry Information Conference.
According to China National Pharmaceutical Industry Information Center, organizer of the annual conference, the main business revenue of the top 100 enterprises in 2020 reached 901.21 billion yuan, down 3.1% year-on-year. This represented the first decline in the past decade due to the impacts of COVID-19.
The average R&D input of the top 100 enterprises was 633 million yuan, and the average R&D intensity, the proportion of R&D expenditure to sales revenue, reached 6.8%, the highest ever.
Yangzijiang Pharmaceutical ranked second on the list and China National Pharmaceutical Group moved two places further to rank first. Jiangsu Hengrui Medicine also climbed up from 10th place to 4th place this time.
Contact us at english@jschina.com.cn
